Galmed Pharmaceuticals Ltd expected to post a loss of 32 cents a share - Earnings Preview

Eocene

25/03/2024 11:05

* Galmed Pharmaceuticals Ltd  GLMD.OQ   GLMD.O  is expected
to show no change in quarterly revenue when it reports 
results on March 27 (estimated) for the period ending December
31 2023
    * 
    * ​LSEG's mean analyst estimate for Galmed Pharmaceuticals
Ltd is
for a loss of 32 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $1.00​, above​ its last closing price
of $0.31. ​​​

This summary was machine generated March 25 at 11:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)